Vaxart to Present at Two Upcoming Medical Meetings

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company
developing oral recombinant vaccines that are administered by tablet
rather than by injection, today announced that new preclinical data on
its intranasal Chikungunya virus (CHIKV) study will be highlighted in an
oral presentation at the 28th European Congress of Clinical Microbiology
and Infectious Diseases (ECCMID), taking place from April 21-24, 2018 in
Madrid, Spain.

Details of the presentation are as follows:

       

Presentation Title:

An oral vaccine approach against Chikungunya Virus (CHIKV)

Date & Time:

Monday, April 23, 2018 at 4:48 PM CEST

Authors:

Roberto Mateo, et al.

Session:

New Kids on the Block – Future Vaccines in Development
 

Additionally, Sean Tucker, Ph.D., founder and chief scientific officer
of Vaxart, will be presenting clinical data from multiple Phase 1 and
Phase 2 studies of its norovirus and influenza oral tablet vaccines at
the upcoming 2018 Annual Conference on Vaccinology Research (ACVR)
sponsored by the National Foundation for Infectious Diseases (NFID),
taking place from April 23-25, 2018 in Bethesda, MD.

Details of the presentation are as follows:

     

Presentation Title:

Mucosal Immune Responses Following Oral Tablet Delivery in
Humans of Vaccines to Prevent Influenza or Norovirus Infection

Date & Time:

Monday, April 23, 2018 at 12:30 PM ET

Authors:

Sean Tucker, et al.

Session:

New Developments in Influenza Vaccines
 

“We look forward to sharing the data from these vaccine programs with
the international scientific community this month at ECCMID and the NFID
Annual Conference on Vaccinology Research,” said Wouter Latour,
president and chief executive officer of Vaxart. “Our oral tablet
vaccines have the potential to significantly impact global public
health, and this data further validates our oral vaccine platform for
two important indications.”

All recent publications are available on the Vaxart website under
Newsroom at www.vaxart.com.

About Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing
oral recombinant protein vaccines based on its proprietary oral vaccine
platform. Vaxart’s vaccines are designed to generate broad and durable
immune responses that protect against a wide range of infectious
diseases and may be useful for the treatment of chronic viral infections
and cancer. Vaxart’s vaccines are administered using a convenient room
temperature-stable tablet, rather than by injection. Vaxart believes
that tablet vaccines are easier to distribute and administer than
injectable vaccines, and have the potential to significantly increase
vaccination rates. Vaxart’s development programs include oral tablet
vaccines that are designed to protect against norovirus, seasonal
influenza and respiratory syncytial virus (RSV), as well as a
therapeutic vaccine for human papillomavirus (HPV). Vaxart is also
developing several small-molecule antiviral drug candidates, including
teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV
types 6 and 11. For more information, please visit www.vaxart.com.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, results from preclinical
and clinical trials, beliefs and expectations of management are
forward-looking statements. These forward-looking statements may be
accompanied by such words as “believe,” “could,” “potential”, “will” and
other words and terms of similar meaning. Examples of such statements
include, but are not limited to, statements relating to the Vaxart’s
ability to develop and commercialize its product candidates, clinical
results and trial data, Vaxart’s ability to obtain and maintain
regulatory approval of its product candidates and Vaxart’s reliance on
third party funding and grants. Vaxart may not actually achieve the
plans, carry out the intentions or meet the expectations or projections
disclosed in our forward-looking statements and you should not place
undue reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions, expectations
and projections disclosed in the forward-looking statements. Various
important factors could cause actual results or events to differ
materially from the forward-looking statements that Vaxart makes, that
Vaxart’s product candidates may not be approved by the FDA or non-U.S.
regulatory authorities; that, even if approved by the FDA or non-U.S.
regulatory authorities, Vaxart’s product candidates may not achieve
broad market acceptance; and the risks described in the “Risk Factors”
sections of the Registration Statement on Form S-4 (file no. 333-222009)
and of Vaxart’s periodic reports filed with the SEC. Vaxart does not
assume any obligation to update any forward-looking statements, except
as required by law.

Contacts

Stern Investor Relations
Carl Mauch, 212-362-1200
vaxart@sternir.com